What is CNBX Pharms's earnings per share (EPS)?

CNBX Pharms (CNBX) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CNBX Pharms Financials

CNBX

Source SEC Filings (10-K/10-Q) Data as of May 31, 2026 Currency USD FYE August

This page shows CNBX Pharms (CNBX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 21 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CNBX FY2025 2026-06-24

CNBX’s reported business mechanic is cash-burn reduction through retrenchment, while a liability-heavy balance sheet overwhelms the operating base.

Versus two years earlier, cash burn narrowed as R&D spending dropped from $1.2M to $195K; because commercial activity remained tiny, that improvement looks like retrenchment rather than a business beginning to fund itself. Meanwhile, liabilities stayed near $2.5M while total assets shrank to just $18K, so the pressure now comes mainly from having almost no operating cushion left.

A current ratio under 0.1x, plus cash of just $15K against current liabilities near $2.5M, means near-term obligations are far larger than near-term resources. That points to a business relying on financing, restructuring, or creditor patience rather than ordinary cash generation to bridge the gap.

The jump in share count to 554.0M shares did not rebuild liquidity, with cash still at only $15K. Ownership claims expanded much faster than the cash buffer, suggesting balance-sheet maintenance has become as important as operating development.

Financial Health Signals

Financial health score pending refresh

We are recalculating CNBX Pharms's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

CNBX Pharms generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$0.00

CNBX Pharms earned $0.00 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$15K

YoY-42.8%

5Y CAGR-54.5%

10Y CAGR-5.0%

CNBX Pharms held $15K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

554M

CNBX Pharms had 554M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

YoY-100.0%

CNBX Pharms invested $0 in research and development in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

CNBX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0-100.0%	$130K-68.3%	$410K+1269.1%	$30K	$0-100.0%	$7K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$0-100.0%	$195K-54.9%	$432K-63.5%	$1.2M-33.2%	$1.8M+5.3%	$1.7M
SG&A Expenses	N/A	$518K-43.0%	$910K-49.5%	$1.8M+117.3%	$829K-36.7%	$1.3M
Operating Income	N/A	-$583K+37.4%	-$931K+68.5%	-$3.0M-13.6%	-$2.6M+14.6%	-$3.0M
Interest Expense	$46K+375.6%	-$17K	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	-$3.7M-16.6%	-$3.2M+57.2%	-$7.5M
EPS (Diluted)	$0.00	$-0.02+95.2%	$-0.42+88.3%	$-3.59	$-0.02	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$0	$0	$0	N/A	$0	$0	$0	N/A
Cost of Revenue	$0	$0	N/A	N/A	$0	$0	N/A	N/A
Gross Profit	$0	$0	N/A	N/A	$0	$0	N/A	N/A
R&D Expenses	N/A	$0	$0	N/A	$0	$0	$0	N/A
SG&A Expenses	N/A	$73K	N/A	N/A	$40K-37.6%	$65K+75.8%	$37K	N/A
Operating Income	N/A	-$73K	N/A	N/A	-$40K+37.6%	-$65K-75.8%	-$37K	N/A
Interest Expense	N/A	N/A	$46K	N/A	N/A	N/A	$3K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$44K	N/A	N/A	-$60K+14.4%	-$70K-103.2%	-$34K	N/A
EPS (Diluted)	$0.00	$0.00	$0.00	N/A	$0.00	$0.00	$-0.00	N/A

CNBX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$18K-41.3%	$31K-93.7%	$499K-38.5%	$811K-73.7%	$3.1M+38.7%	$2.2M
Current Assets	$18K-41.3%	$31K-86.0%	$224K+13.1%	$198K-87.5%	$1.6M+71.1%	$930K
Cash & Equivalents	$15K-42.8%	$26K-79.6%	$130K+10.4%	$118K-91.5%	$1.4M+78.3%	$778K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M+0.1%	$2.5M-0.2%	$2.5M+406.4%	-$821K-164.5%	$1.3M+179.9%	$455K
Current Liabilities	$2.5M+0.1%	$2.5M-0.2%	$2.5M+3.0%	$2.4M+91.9%	$1.3M+179.9%	$455K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.5M-0.7%	-$2.5M-22.9%	-$2.0M-223.6%	$1.6M-9.6%	$1.8M+2.3%	$1.8M
Retained Earnings	-$25.3M-1.3%	-$25.0M-2.9%	-$24.3M-18.1%	-$20.5M-22.1%	-$16.8M-23.4%	-$13.6M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$13K-14.1%	$15K+33.5%	$11K-39.5%	$18K-1.0%	$19K-63.3%	$51K+127.1%	$22K-28.9%	$31K
Current Assets	$13K-14.1%	$15K+33.5%	$11K-39.5%	$18K-1.0%	$19K-63.3%	$51K+127.1%	$22K-28.9%	$31K
Cash & Equivalents	$9K-21.9%	$12K+57.8%	$8K-49.0%	$15K+10.7%	$14K-70.1%	$46K+163.4%	$17K-34.4%	$26K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.7M+4.9%	$2.5M-1.4%	$2.6M+2.8%	$2.5M-1.6%	$2.6M-2.5%	$2.6M+3.3%	$2.5M+1.0%	$2.5M
Current Liabilities	$2.7M+4.9%	$2.5M-1.4%	$2.6M+2.8%	$2.5M-1.6%	$2.6M-2.5%	$2.6M+3.3%	$2.5M+1.0%	$2.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.7M-5.0%	-$2.5M+1.5%	-$2.6M-3.1%	-$2.5M+1.6%	-$2.5M+1.3%	-$2.6M-2.2%	-$2.5M-1.4%	-$2.5M
Retained Earnings	-$25.6M-0.6%	-$25.4M-0.2%	-$25.4M-0.5%	-$25.3M-0.6%	-$25.1M-0.2%	-$25.1M-0.3%	-$25.0M-0.1%	-$25.0M

CNBX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$244K-117.1%	-$113K+93.3%	-$1.7M+32.6%	-$2.5M+10.2%	-$2.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0-100.0%	$113K+359.4%	$25K-2.1%	$25K-96.1%	$645K-80.4%	$3.3M
Financing Cash Flow	N/A	$28K-72.5%	$100K-74.3%	$390K-84.1%	$2.5M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$48K-56.0%	-$31K+35.6%	-$47K-66.1%	-$29K+45.1%	-$52K-0.7%	-$52K-32.2%	-$39K+19.0%	-$48K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	$0	$0	$0	$0	$0	$0
Financing Cash Flow	$45K+28.6%	$35K-12.5%	$40K+33.3%	$30K+50.1%	$20K-75.0%	$80K+166.7%	$30K+2281.0%	$1K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CNBX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-448.3%-221.2pp	-227.1%+9633.3pp	-9860.4%	N/A	-42524.1%
Net Margin	N/A	N/A	N/A	-12428.2%	N/A	-104337.9%
Return on Equity	N/A	N/A	N/A	-228.1%-51.2pp	-176.9%+246.3pp	-423.2%
Return on Assets	N/A	N/A	N/A	-459.0%-355.3pp	-103.8%+232.7pp	-336.5%
Current Ratio	0.010.0	0.01-0.1	0.090.0	0.08-1.2	1.25-0.8	2.04
Debt-to-Equity	-1.010.0	-1.01+0.2	-1.25-0.7	-0.50-1.2	0.70+0.4	0.26
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-296.0%	N/A	N/A	-320.8%-183.1pp	-137.8%+16.2pp	-154.0%	N/A
Current Ratio	0.000.0	0.010.0	0.000.0	0.010.0	0.01-0.0	0.02+0.0	0.010.0	0.01
Debt-to-Equity	-1.000.0	-1.010.0	-1.000.0	-1.010.0	-1.01+0.0	-1.02-0.0	-1.010.0	-1.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$2.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

PaxMedica, Inc. PXMD

$2.8M

Marizyme MRZM

$40K

Bassline Productions Inc BSSP

$37K

Itoco Inc ITMC

$41K

Navidea Biopharm NAVB

$50K

Frequently Asked Questions

What is CNBX Pharms's annual revenue?

CNBX Pharms (CNBX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is CNBX Pharms's revenue growing?

CNBX Pharms (CNBX) revenue declined by 100% year-over-year, from $130K to $0 in fiscal year 2025.

What are CNBX Pharms's total assets?

CNBX Pharms (CNBX) had $18K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does CNBX Pharms have outstanding?

CNBX Pharms (CNBX) had 554M shares outstanding as of fiscal year 2025.

What is CNBX Pharms's current ratio?

CNBX Pharms (CNBX) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is CNBX Pharms's debt-to-equity ratio?

CNBX Pharms (CNBX) had a debt-to-equity ratio of -1.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is CNBX Pharms's debt-to-equity ratio negative or unusual?

CNBX Pharms (CNBX) has negative shareholder equity of -$2.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.